MARKET

EYPT

EYPT

EyePoint
NASDAQ
13.30
+0.26
+1.99%
After Hours: 13.30 0 0.00% 19:54 07/17 EDT
OPEN
12.76
PREV CLOSE
13.04
HIGH
13.69
LOW
12.61
VOLUME
1.28M
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
9.40
MARKET CAP
1.12B
P/E (TTM)
-3.7992
1D
5D
1M
3M
1Y
5Y
1D
EyePoint Pharmaceuticals Settles DEXYCU Case, Enhances Compliance Oversight
TipRanks · 11h ago
EyePoint to Pay $4.7M to Resolve Allegations of False Claims Act Violations
Dow Jones · 11h ago
EYEPOINT - CORPORATE INTEGRITY AGREEMENT HAS FIVE-YEAR TERM BEGINNING JULY 13, 2026 - SEC FILING
Reuters · 12h ago
EyePoint to pay $4.6M to settle with DoJ over kickback claims
Seeking Alpha · 17h ago
EyePoint to pay $4.6M to resolve False Claim Act allegations
TipRanks · 18h ago
EyePoint Pharmaceuticals To Pay $4.6M to Resolve False Claims Act Allegations
Benzinga · 18h ago
This Rambus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 1d ago
EyePoint grants inducement stock options for 63,500 shares at $13.85 each
PUBT · 1d ago
More
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Webull offers EyePoint Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.